Solidus Biosciences Inc.
This article was originally published in Start Up
Executive Summary
Why are fewer drugs obtaining market approval in recent years? The answer is likely complex, but toxicology issues may be part of the problem. Solidus Biosciences aims to provide pharmaceutical companies with the tools it needs for early stage tox screening. Its MetaChip, short for Metabolizing Enzyme Toxicology Assay chip, is a high through-put biochip capable of screening compounds for their toxicological and metabolic properties in a single test run.